Physician profile
Sunil Tulpule
NPI 1366988024
$36,454.86
in general payments reported to CMS, 2019-2025
22 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $301 · 2021: $302 · 2022: $8,410 · 2023: $3,470 · 2024: $5,668 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $11K · Consulting Fee: $10K · Food and Beverage: $3,592 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,200 · Travel and Lodging: $688 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $10,500.00 |
| Consulting Fee | $10,432.25 |
| Food and Beverage | $3,591.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,200.00 |
| Travel and Lodging | $687.55 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $19,097.68 | 2021-2025 | |
| Genzyme Corporation | $6,431.54 | 2022-2025 | |
| Syndax Pharmaceuticals, INC. | $3,852.23 | 2025 | Revuforj |
| Kyowa Kirin, INC. | $2,916.51 | 2023-2025 | Poteligeo |
| Genmab U.S., INC. | $1,546.80 | 2023-2024 | Epkinly |
| Abbvie INC. | $603.35 | 2020-2025 | Venclexta |
| Seagen INC. | $425.60 | 2021-2023 | Adcetris |
| Amgen INC. | $264.65 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $235.70 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $168.44 | 2020-2023 | Epkinly |
| Novocure INC. | $160.07 | 2022-2023 | Optune |
| Alexion Pharmaceuticals, INC. | $127.89 | 2023 | Ultomiris |
| Astrazeneca Pharmaceuticals Lp | $124.97 | 2022 | |
| Janssen Biotech, INC. | $117.15 | 2021-2022 | |
| Pfizer INC. | $105.78 | 2022-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $100.34 | 2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $53.10 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $46.24 | 2020-2021 | |
| Celgene Corporation | $22.52 | 2023 | Pomalyst |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Adaptive Biotechnologies Corporation | $20.98 | 2025 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Tulpule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.